Funding for innovative methods to screen and treat potentially fatal disorders in newborns, including genetic conditions needing screening advancements.
Funder: National Institutes of Health
Due Dates: November 5, 2026 (Renewal/resubmission/revision) | February 5, 2027 (New) | March 5, 2027 (Renewal/resubmission/revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/resubmission/revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/resubmission/revision) | November 16, 2027 (Closing date)
Funding Amounts: No budget cap; requests must reflect project needs; maximum project period of 5 years; no cost sharing required
Summary: Supports innovative screening approaches and therapies for newborn-screened disorders and potentially fatal or disabling genetic conditions suitable for future screening.
Key Information: Clinical trials are optional; all applications must explain their innovation and relevance to newborn screening.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) administers this NIH R01 opportunity for research on novel newborn screening approaches and therapeutic interventions. It supports conditions already included in newborn screening panels and potentially fatal or disabling genetic conditions that could benefit from presymptomatic detection and early treatment. Accurate screening tests and demonstrated benefits of intervention can help establish the case for adding conditions to screening panels.
Basic, behavioral, translational, and clinical research are welcome. Areas of interest include screening assay development and validation, higher-tier tests reducing false positives, artificial intelligence, low-resource screening methods, alternative specimen types, preclinical therapies, comparative effectiveness, clinical trials, genotype–phenotype studies, access to care, and embedded ethical, legal, and social research. The R01 supports long-term projects or work expanding knowledge in established areas.